Webinars2024-06-20T16:10:02+00:00

Upcoming Webinars

Recent Webinars

Past Webinars

14April, 2024

Antisense approaches for the treatment of Duchenne muscular dystrophy and recent advances to address DMD brain comorbidities

Categories: Past Webinars|

Date: May 23, 2024 Time: 8am PDT / 11am EDT / 5pm CEST Title: Antisense approaches for the treatment of Duchenne muscular dystrophy and recent advances to address DMD brain comorbidities Description: This presentation will cover the development of ASO-based approaches for the treatment of Duchenne ...

14April, 2024

2023 Annual Meeting Poster Awardee Spotlight: Stan and Moravčík

Categories: Past Webinars|

Date: May 16, 2024 Time: 8am PDT / 11am EDT / 5pm CEST Title: Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy Description: The Validation Lab was established in 2015 with support from the Duchenne Parent Project ...

14April, 2024

In-silico siRNA Off-Target Predictions: What Should We Be Looking For?

Categories: Past Webinars|

Date: May 2, 2024 Time: 8am PDT / 11am EDT / 5pm CEST Title: In-silico siRNA Off-Target Predictions: What Should We Be Looking For? Description: Assessing sequence-dependent off-target risks is a critical step during siRNA development to ensure the safety and specificity of therapeutic candidate molecules. ...

12April, 2024

In vivo Optical Control of Gene-Silencing in Japanese Medaka Fish Embryos

Categories: Past Webinars|

Time: 8am PDT / 11am EDT / 5pm CEST Date: April 25, 2024 Title: In vivo Optical Control of Gene-Silencing in Japanese Medaka Fish Embryos Description: The siRNA oligonucleotide duplex inherent to biology, functions by binding and cleaving mRNA, a process known as the RNA interference ...

16February, 2024

Meet OTS’ New BOD Trainee Reps

Categories: Past Webinars|

Time: 8AM PST | 11AM EST | 5PM CET Date: February 22, 2024 Title: Advancing Therapeutic Approaches for Erythropoietic Protoporphyria Description: Currently, no curative treatment is available for the rare disease erythropoietic protoporphyria (EPP). The genetic background of EPP is well understood; a loss-of-function mutation on ...

Go to Top